Analysts' Top 5 Price Targets of January 8, 2026
Reading Time: 4 minutes
Eckert & Ziegler [DE0005659700] NuWays assigns a Buy rating with a price target of €23 (45% upside potential) Targeted radiopharmaceutical therapies are considered the next phase of cancer treatment, as they deliver radiation precisely to tumor cells while combining better tolerability with high efficacy. The nuclear medicine market is expected to grow by approximately 17% annually until 2029. As an essential supplier of radioisotopes, Eckert & Ziegler stands to benefit structurally from this growth since every radiopharmaceutical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
